What does CHLOE—Embryo Quality Module cost?

AI-driven embryo assessment software for IVF labs—pricing currently opaque; purchase requires direct negotiation

CHLOE is a full platform with different modules that support various stages of the IVF process, with CHLOE EQ (Embryo Quality Insights) and CHLOE OQ being among the most important . CHLOE EQ helps embryologists assess the quality and viability of embryos based on how they develop in the first five days after fertilization . Acquiring CHLOE for your fertility laboratory involves no published list price, no GSA contract, and no standard per-unit cost. Most labs negotiate pricing directly with Fairtility based on volume, deployment model, and support tier. Estimated acquisition cost ranges from $50,000–$200,000+ annually depending on clinic size, but MedSource currently has no aggregate quote database for this product. This article will be updated as real-world pricing data accumulates.

What the typical range is

Published pricing does not exist. Fairtility, the Israeli company that manufactures CHLOE, positions this as enterprise software licensed to individual clinics, not commodity hardware. CHLOE is commercially used with tens of thousands of patients outside of the U.S. , yet no standardized fee-for-service or subscription tier is publicly disclosed.

Indirect signals suggest multi-year contracts:

Fairtility raised $15 million in Series A funding in 2022 , typical for venture-backed software at early commercialization, implying venture-scale sales cycles and deal sizes.

CHLOE Blast™ achieved FDA 510(k) clearance in September 2025 , opening the U.S. market now—suggesting price negotiation is only beginning in the largest market.

• No lease-to-own, perpetual-license, or per-cycle pricing models have been disclosed.

Assumption for planning: Budget $75,000–$150,000 annually for a 20–50 embryo/month lab. This aligns with comparable clinical-grade AI platforms in pathology and radiology, but remains unverified.

What pushes price up—features, certifications, support tier

FDA 510(k) Clearance & Regulatory Status

CHLOE Blast™ is the first and only FDA-cleared machine learning AI-powered clinical decision support software for embryo assessment . This regulatory precedent commands premium pricing in the U.S. market. Labs outside the U.S. may access older CE-marked versions (approved since ~2022) at lower cost.

Clinical Performance & Validation

CHLOE has blastocyst prediction accuracy of 96% and implantation prediction accuracy of 73% . CHLOE's effectiveness has been confirmed in multiple peer-reviewed studies published in top journals like Human Reproduction and Fertility & Sterility, with more than 80 abstracts presented at major fertility conferences like ESHRE and ASRM . Labs seeking peer-reviewed evidence to support institutional adoption will pay more for validated, published data than for experimental tools.

Integration Depth & EMR Connectivity

CHLOE automates embryo stage annotation and connects directly with electronic medical records (EMR) to cut administrative workload . Labs running legacy EMRs (older Cerner, Medidata, fertility-specific systems) may require custom integration work, adding cost. Labs with modern cloud-based systems may see faster deployment.

Multi-Module Licensing CHLOE is sold as modular: CHLOE EQ (embryo quality), CHLOE OQ (oocyte/egg quality), and CHLOE Blast (blastocyst prediction). CHLOE Blast is part of the CHLOE AI platform for embryo assessment . Single-module vs. full-suite adoption will shift pricing significantly. Full integration costs more.

Incubator Compatibility

CHLOE works with time-lapse incubators such as Embryoscope or Geri; these incubators enable uninterrupted culture and allow observation of development in greater detail, but also record masses of data that even the highest-trained embryologist struggles to process . Labs already owning compatible time-lapse systems pay only for CHLOE software; labs needing to upgrade incubator hardware pay 2–3× more.

Support & Training Vendor support tiers (e.g., 24/7 hotline vs. business-hours-only; on-site training vs. remote) are not disclosed. Anticipate $10,000–$30,000 annually for premium support in the U.S.

What pushes price down—refurbished, older generation, lease, GPO contracts

Regional Licensing & Non-U.S. Pricing

CHLOE is commercially used with tens of thousands of patients outside the U.S. across Europe, Canada and Asia Pacific . Labs in lower-cost regions (Latin America, Asia-Pacific) may negotiate 30–50% discounts relative to U.S. pricing. CE-marked (pre-FDA) versions may still be available at lower cost in some markets.

Multi-Year Commitment Discounts No multi-year pricing has been disclosed, but vendor practice suggests 10–20% discounts for 3–5 year upfront commitments vs. annual renewal.

Group Purchasing Organization (GPO) Agreements No CHLOE-specific GPO contracts (e.g., through Novation, Premier, or MedAssets) are publicly listed. Fairtility, as a private Israeli company, may not be aggressive on GPO pricing. Industry-wide adoption below 50 U.S. clinics makes GPO leverage difficult.

Partial Deployment (Single-Module or Low-Volume Labs) Labs starting with CHLOE EQ only (embryo quality, not egg quality) may pay 40–60% less than full-suite labs. Low-volume labs (< 5 embryos/month) may be declined by vendors or assigned to high per-cycle pricing rather than flat annual fees.

Hidden costs—install, training, calibration, consumables, service contracts

Implementation & Integration Setup Expect $5,000–$20,000 for EMR integration, API configuration, and network setup. Labs with complex hybrid EMR architectures (e.g., Cerner primary + proprietary fertility module) may hit $25,000+.

Initial Training & Validation

CHLOE can remove 17 of the 24 steps embryologists perform, reducing time per cycle from 9.76 to 6.43 hours—a 33% reduction per cycle with an associated 50% increase in embryology annual cycle capacity . This operational benefit requires trained staff. Budget $3,000–$8,000 for initial embryologist training, validation studies (comparing CHLOE scores to manual grading), and change-management support.

No Consumables, but Software Updates Are Mandatory CHLOE does not require physical consumables (cartridges, reagents, chips). However, annual software updates and algorithm refinements are typical for AI platforms. These are usually bundled in annual license fees but may incur additional cost if the lab is on an older version.

Incubator Upgrade or Replacement If your lab is not running a compatible time-lapse incubator (Embryoscope, Geri, Cook STILL, etc.), CHLOE will not function. Time-lapse incubator cost ranges from $80,000–$150,000 per unit. This is a separate capital expense, not bundled in CHLOE pricing. Do not underestimate this upfront barrier.

Annual Maintenance & Support Contracts Support is likely bundled in licensing but expect $8,000–$15,000 annually for standard SLA (Service Level Agreement) renewals once the initial contract ends. Premium 24/7 support may add $5,000–$10,000/year.

Data Storage & Cloud Hosting CHLOE operates as cloud-based or hybrid (on-premise + cloud). Labs with high patient volume (> 500 cycles/year) may see data storage costs rise. Estimate $2,000–$5,000/year for secure cloud infrastructure, though this may be included in licensing.

How to negotiate—concrete tactics

1. Benchmark Against Competitors

Fairtility's CHLOE platform differentiates itself through explainable AI, real-time monitoring, and transparent algorithm design, gaining traction across Europe and Asia-Pacific . Also evaluate Vitrolife iDAScore, AIVF EMA, and CooperSurgical OvaScience portfolios. Request RFQs from at least two vendors; Fairtility will respond if you demonstrate serious capital allocation.

2. Request Outcome-Based Pricing Propose a pilot: Pay a reduced first-year rate (e.g., $40,000–$60,000) in exchange for Fairtility using your lab's data for publication (de-identified). This reduces vendor risk and may unlock flexibility.

3. Demand Total Cost of Ownership (TCO) Transparency Require Fairtility to provide a written breakdown of:

• Software license fee
• EMR integration cost
• Training & validation
• Annual support
• Incubator compatibility (do you need to upgrade?)
• Data storage & hosting

Without this, you cannot compare CHLOE to alternatives.

4. Negotiate Multi-Clinic Discounts If your health system operates 2+ fertility labs, ask for volume pricing. A 10–15% discount per additional clinic is standard in enterprise software.

5. Clarify Termination & Data Portability Ensure your contract specifies:

• Exit terms (if CHLOE underperforms, can you cancel after Year 2?)
• Data export format (can you extract historical embryo scores and images if you switch vendors?)
• IP ownership (do you own the CHLOE annotations, or does Fairtility retain research rights?)

6. Leverage FDA Clearance Timing The September 2025 FDA 510(k) clearance is recent. Fairtility may offer lower introductory U.S. pricing to accelerate market share. Lock in pricing now if you're willing to commit to a 3-year deal.

When the price feels off—red flags

No Incubator Already? Red Flag. If a vendor quotes CHLOE pricing but your lab lacks a compatible time-lapse incubator, the total capital outlay could easily exceed $200,000 in Year 1. Clarify this before proceeding.

Vague Support Terms If Fairtility will not commit to specific response times (e.g., critical bugs < 4 hours; updates < 48 hours), walk away. AI-dependent workflow cannot tolerate 2-week support tickets.

No Published Clinical Evidence in Your Incubator Model

The integration of AI algorithms, such as CHLOE-EQ, into different time-lapse systems requires clinical and biological validation, and this is the first study presenting the efficacy of prediction of CHLOE-EQ with GERI data . If CHLOE has not been validated specifically on your incubator model (Embryoscope vs. Geri vs. others), demand a lower price or a longer trial period.

Per-Cycle Pricing Without Transparency If Fairtility proposes "per-embryo" or "per-cycle" pricing but won't disclose the unit rate, assume you're being priced for high-volume labs. Request flat annual fees instead.

Locked Incubator Ecosystem Some vendors bundle CHLOE discounts with incubator leases, making it expensive to switch later. Confirm CHLOE will work with any compatible incubator, not just the vendor's own.

No Service Level Agreement (SLA) Cloud-based AI without uptime guarantees is unacceptable. Minimum acceptable SLA: 99.5% availability with compensation (service credits) for downtime > 30 minutes.

Sources

Fairtility press release (Sept. 3, 2025): CHLOE Blast™ FDA 510(k) clearance announcement

FDA 510(k) submission document for CHLOE BLAST (K243851), August 15, 2025: non-clinical performance data and clinical validation study (U.S. sites, 2020–2021 patient data)

Kahraman, S., et al. "Can CHLOE (an AI-based embryologist assistant) automatically predict on day 3 whether an embryo will become a blastocyst, be utilised and/or implant?" Fertility & Sterility, October 2022: morphokinetic accuracy, blastulation prediction AUC=0.83, embryo utilization prediction AUC=0.79

Fairtility research summary (ASRM 2022): embryologist time reduction from 9.76 to 6.43 hours per cycle; 50% increase in annual cycle capacity

Future Market Insights, AI-Powered Embryo Selection Market report (December 2025): competitive landscape analysis (Vitrolife, CooperSurgical, AIVF, Esco Lifesciences)

---

Status: This article reflects publicly available information as of May 2026. Fairtility does not disclose CHLOE pricing. MedSource will update this page as vendor quotes accumulate. If you have recent quotes or pricing intel, contact our research team.